Bristol-Myers Squibb sets Vagistat-1 review

Published on .

Bristol-Myers Squibb Co. is conducting a review for Vagistat-1, a reduced-time treatment for yeast infection, between roster agencies Gotham Inc. and Wells Rich Greene BDDP. The product, which is the latest in a series of reduced-time treatments for yeast infections, has not yet received FDA approval. Those close to the product introduction said it is expected to receive FDA approval by the first quarter of next year.

Copyright October 1996, Crain Communications Inc.

In this article:
Most Popular